Medicine
Microbiome-Immune Interactions in Ulcerative Colitis
Quick fact
The gut microbiome in ulcerative colitis is typically less diverse and shows a shift toward pro-inflammatory bacteria, while the immune system mistakenly attacks the colon's lining, leading to chronic inflammation and ulceration.
Why this is interesting
Your gut is home to trillions of bacteria, yet your immune system rarely attacks them. In ulcerative colitis, that peace treaty breaks down—what goes wrong?
Read the full explanation
Understanding Microbiome-Immune Interactions in Ulcerative Colitis
Imagine your colon as a crowded city where millions of bacteria (the microbiome) live inside a protective wall—the intestinal lining. Normally, the wall is strong and the immune system, like a tolerant police force, ignores the harmless bacteria. But in ulcerative colitis, the wall becomes leaky, and bacteria or their components escape into the underlying tissue. This triggers the immune system to mount a full-scale attack, not just on the bacteria but also on the colon's cells. The result is inflammation, ulcers, and symptoms like diarrhea and abdominal pain. This process is a tug-of-war between the need to defend against harmful microbes and the need to tolerate beneficial ones.
A deeper explanation
Ulcerative colitis arises from a complex interplay between genetic susceptibility, the gut microbiome, and immune responses. The intestinal epithelium—a single layer of cells—acts as a physical and chemical barrier, preventing microbial invasion. In UC, this barrier is often compromised, leading to increased permeability (leaky gut). As a result, microbial products such as lipopolysaccharide (LPS) and flagellin activate pattern recognition receptors (like TLRs and NLRs) on immune cells, stimulating pro-inflammatory signaling pathways such as NF-κB. This triggers the recruitment of neutrophils and macrophages, and activates T helper cells, particularly Th1 and Th17, which produce cytokines like TNF-α, IL-17, and IFN-γ. In UC specifically, there is also an atypical Th2 response involving IL-13. These cytokines disrupt the epithelial barrier further, promote apoptosis of colonocytes, and drive the chronic inflammation and ulceration typical of UC. Additionally, dysbiosis—an altered microbiome composition—reduces beneficial bacteria that produce anti-inflammatory metabolites like butyrate, which normally nourish colonocytes and regulatory T cells. The loss of these protective signals and the increase of pro-inflammatory bacteria perpetuate a vicious cycle of inflammation. Understanding this interplay explains why antibiotics or probiotics can influence disease activity and why immunomodulatory therapies targeting specific cytokines (e.g., anti-TNF) or integrins are effective. It also highlights potential strategies like fecal microbiota transplantation to restore a healthier microbial community.